Akero Therapeutics ( (AKRO) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Akero Therapeutics’ stock has seen a remarkable rise following the release of groundbreaking results from its Phase 2b SYMMETRY trial for its lead drug, efruxifermin, which showed significant improvements in liver fibrosis for patients with MASH. These promising results have prompted major analysts like Morgan Stanley, Citi, and Canaccord to increase their price targets for the company. This optimism is based on the drug’s potential as a cornerstone treatment in an underserved market, suggesting a lucrative future and a competitive edge over existing therapies.
More about Akero Therapeutics
YTD Price Performance: 83.30%
Average Trading Volume: 1,047,303
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.59B
For further insights into AKRO stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.